This “Mydriasis - Pipeline Insight, 2021,” report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in Mydriasis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Mydriasis is the medical term for an unusual dilation or widening of the pupils. This may be caused by an injury, psychological factors, or due to the uptake of certain drugs or medications. The characteristic symptom of mydriasis is dilated pupils that do not get bigger or smaller in response to changes in light. When the pupils are dilated, the eyes become more sensitive to light. This can lead to blurry vision, as well as, in some cases, a general feeling of constriction around the forehead and eyes. Treatment approaches try to protect the full functionality of the eyes and generally depends on what caused the condition in first.
"Mydriasis - Pipeline Insight, 2021" report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Mydriasis pipeline landscape is provided which includes the disease overview and Mydriasis treatment guidelines. The assessment part of the report embraces, in depth Mydriasis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Mydriasis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
The companies and academics are working to assess challenges and seek opportunities that could influence Mydriasis R&D. The therapies under development are focused on novel approaches to treat/improve Mydriasis.
This segment of the Mydriasis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Phentolamine Ophthalmic Solution: Ocuphire Pharma, Inc.
Phentolamine produces its therapeutic actions by competitively blocking alpha-adrenergic receptors leading to a muscle relaxation and a widening of the blood vessels. The phentolamine ophthalmic solution is being evaluated in phase III stage of development for the treatment of Mydriasis.
There are approx. 5+ key companies which are developing the therapies for Mydriasis. The companies which have their Mydriasis drug candidates in the most advanced stage, i.e. phase III include, Ocuphire Pharma, Inc.
The drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Mydriasis therapeutic drugs key players involved in developing key drugs.
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Mydriasis drugs.
Geography Covered
- Global coverage
Mydriasis Understanding
Mydriasis: Overview
Mydriasis is the medical term for an unusual dilation or widening of the pupils. This may be caused by an injury, psychological factors, or due to the uptake of certain drugs or medications. The characteristic symptom of mydriasis is dilated pupils that do not get bigger or smaller in response to changes in light. When the pupils are dilated, the eyes become more sensitive to light. This can lead to blurry vision, as well as, in some cases, a general feeling of constriction around the forehead and eyes. Treatment approaches try to protect the full functionality of the eyes and generally depends on what caused the condition in first.
"Mydriasis - Pipeline Insight, 2021" report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Mydriasis pipeline landscape is provided which includes the disease overview and Mydriasis treatment guidelines. The assessment part of the report embraces, in depth Mydriasis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Mydriasis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
The companies and academics are working to assess challenges and seek opportunities that could influence Mydriasis R&D. The therapies under development are focused on novel approaches to treat/improve Mydriasis.
Mydriasis Emerging Drugs Chapters
This segment of the Mydriasis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Mydriasis Emerging Drugs
Phentolamine Ophthalmic Solution: Ocuphire Pharma, Inc.
Phentolamine produces its therapeutic actions by competitively blocking alpha-adrenergic receptors leading to a muscle relaxation and a widening of the blood vessels. The phentolamine ophthalmic solution is being evaluated in phase III stage of development for the treatment of Mydriasis.
Mydriasis: Therapeutic Assessment
This segment of the report provides insights about the different Mydriasis drugs segregated based on following parameters that define the scope of the report, such as:
Major Players in Mydriasis
There are approx. 5+ key companies which are developing the therapies for Mydriasis. The companies which have their Mydriasis drug candidates in the most advanced stage, i.e. phase III include, Ocuphire Pharma, Inc.
Phases
This report covers around 5+ products under different phases of clinical development like
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
Mydriasis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
- Oral
- Subcutaneous
- Intravenous
- Intramuscular
- Molecule Type
Products have been categorized under various Molecule types such as
- Bispecific Antibody
- Peptides
- Small molecule
- Gene therapy
- Product Type
The drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
Mydriasis: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Mydriasis therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Mydriasis drugs.
Mydriasis Report Insights
- Mydriasis Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
Mydriasis Report Assessment
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Key Questions Answered
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Mydriasis drugs?
- How many Mydriasis drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Mydriasis?
- What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Mydriasis therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Mydriasis and their status?
- What are the key designations that have been granted to the emerging drugs?
Table of Contents
IntroductionExecutive Summary
Mydriasis: Overview
- Causes
- Mechanism of Action
- Signs and Symptoms
- Diagnosis
- Disease Management
Pipeline Therapeutics
- Comparative Analysis
Therapeutic Assessment
- Assessment by Product Type
- Assessment by Stage and Product Type
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type
Mydriasis - Analytical Perspective
In-depth Commercial Assessment
- Mydriasis companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Mydriasis Collaboration Deals
- Company-Company Collaborations (Licensing/Partnering) Analysis
- Company-University Collaborations (Licensing/Partnering) Analysis
Late Stage Products (Phase III)
- Comparative Analysis
Phentolamine Ophthalmic Solution: Ocuphire Pharma
- Product Description
- Research and Development
- Product Development Activities
Mid Stage Products (Phase II)
- Comparative Analysis
EYN-1601: Eyenovia, Inc.
- Product Description
- Research and Development
- Product Development Activities
Preclinical Stage Products
- Comparative Analysis
Drug Name: Company Name
- Product Description
- Research and Development
- Product Development Activities
Inactive Products
- Comparative Analysis
Mydriasis Key Companies
Mydriasis Key Products
Mydriasis- Unmet Needs
Mydriasis- Market Drivers and Barriers
Mydriasis- Future Perspectives and Conclusion
Mydriasis Analyst Views
Mydriasis Key Companies
AppendixList of Tables
Table 1 Total Products for Mydriasis
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive ProductsList of Figures
Figure 1 Total Products for Mydriasis
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Companies Mentioned
A selection of companies mentioned in this report includes:
- Ocuphire Pharma
- Eyenovia Inc.
